Abstract
Thyroid carcinomas exhibit various genetic alterations, including the RET and NTRK fusion genes that are targets for molecular therapies. Thus, detecting fusion genes is crucial for devising effective treatment plans. This study characterized the pathological findings associated with these genes to identify the specimens suitable for genetic analysis. Thyroid carcinoma cases positive for the fusion genes were analyzed using the Oncomine Dx Target Test. Clinicopathological data were collected and assessed. Among the 74 patients tested, 8 had RET and 1 had NTRK3 fusion gene. Specifically, of the RET fusion gene cases, 6 exhibited “BRAF-like” atypia and 2 showed “RAS-like” atypia, while the single case with an NTRK3 fusion gene presented “RAS-like” atypia. Apart from one poorly differentiated thyroid carcinoma, most cases involved papillary thyroid carcinomas (PTCs). Primary tumors showed varied structural patterns and exhibited a high proportion of non-papillary structures. Dysmorphic clear cells were frequently observed. BRAF V600E immunoreactivity was negative in all cases. Interestingly, some cases exhibited similarities to diffuse sclerosing variant of PTC characteristics. While calcification in lymph node metastases was mild, primary tumors typically required hydrochloric acid-based decalcification for tissue preparation. This study highlights the benefits of combining morphological and immunohistochemical analyses for gene detection and posits that lymph node metastases are more suitable for genetic analysis owing to their mild calcification. Our results emphasize the importance of accurate sample processing in diagnosing and treating thyroid carcinomas.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Thyroid carcinomas exhibit various genetic alterations [1], among which the fusion genes are important targets for molecular therapies [2,3,4]. Determining the presence or absence of these fusion genes is essential for developing novel therapeutic strategies. However, conducting comprehensive genetic analyses in every case is difficult because of technical and economic constraints [5, 6]. In Japan, since 2022, the Oncomine Dx Target Test (for thyroid carcinomas) has been approved for the genetic characterization of advanced or recurrent thyroid carcinomas. This has facilitated widespread genetic analysis of thyroid carcinomas using the Oncomine Dx Target Test, which is expected to be performed at many hospitals. Based on this advancement, we conducted detailed pathological examinations of thyroid carcinomas in which the RET and NTRK3 fusion genes were identified using the Oncomine Dx Target Test. This study aimed to elucidate the specific pathological characteristics associated with the RET and NTRK3 fusion genes and effectively identify cases likely to exhibit one or both of these fusion genes in routine diagnostic work. Additionally, we aimed to characterize the specimens that were most suitable for genetic analysis.
Materials and methods
In the present study, we enrolled patients with thyroid carcinoma from the Kanagawa Cancer Center (Yokohama, Japan) who were tested using the Oncomine Dx Target Test between May 2022 and October 2023. The rationale for using the Oncomine Dx Target Test, which is approved for use in Japan for patients with advanced or recurrent thyroid carcinoma, was driven by clinical reasons (the test was outsourced). In addition to detecting the BRAF, RAS, and other mutations, it also targets fusion genes for identification, including ABL1, ALK, AXL, BRAF, ERBB2, ERG, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, PDGFRA, PPARG, RAF1, RET, and ROS1. Among these cases, those in which the fusion genes were detected were selected. Basic clinicopathological data, including age; sex; type of fusion gene; histological findings; fusion gene partners; tumor, nodes, and metastases (TNM) classification (UICC 8th edition); and outcome, were obtained from electronic medical records and pathological diagnostic reports. The response to radioactive iodine (RAI) therapy follows the American Thyroid Association Guidelines [7]. Subsequently, the specimens were thoroughly reviewed to validate these data and conduct additional pathological analyses. These analyses included assessing the presence or absence of papillary thyroid carcinoma (PTC) nuclei, counting mitoses per 10 high-power fields, determining the presence or absence of squamous solid nests, and performing immunohistochemical analyses using BRAF V600E (Clone: VE1), Ki-67 (Clone: 30–9), and Pan-TRK (Clone: EPR17341). PTC nuclei were assessed based on a previous report using a 3-point scoring system, with a score of 2 or higher being defined as PTC nuclei [8]. Furthermore, based on a previous report, we also assessed whether “BRAF-like” atypia or “RAS-like” atypia was present [9]. The primary tumor was analyzed; however, in cases where the primary tumor could not be obtained, recurrent lymph node metastases or metastases in other organs submitted for the Oncomine Dx Target Test were used. Given the known high frequency of RET fusion genes in diffuse sclerosing variant of PTC (DSVPTC) [10,11,12], we adopted the diagnostic criteria based on a previous report for identifying relevant factors in this study [9]. At the structural level, the patterns of papillary, follicular, and solid/trabecular/insular (STI) structures were analyzed, and their percentages out of the total were evaluated. Only the percentages of papillary, follicular, and STI structures were included, excluding other structures from the denominator. The degree of fibrosis and calcification was also evaluated. The degree of fibrosis was expressed as a percentage of the total tumor lesions. For calcification, two distinct types were evaluated: psammoma bodies (a small, concentrically layered calcification formed around a necrotic tumor cell nucleus, typically found within the tumor stroma and lymphatic vessels [13]), and coarse calcification. Henceforth, the term “calcification” will refer exclusively to the latter, that is, coarse type. Calcification was evaluated on a scale of 0–3B. Each level was defined as follows: 0, no obvious calcification; 1, psammoma bodies or calcified nests that did not require a decalcification procedure; 2A, requiring only ethylenediaminetetraacetic acid (EDTA)-based decalcification for less than half of the specimens; 2B, requiring only EDTA-based decalcification for more than half of the specimens; 3A, requiring hydrochloric acid-based decalcification for less than half of the specimens; 3B, requiring hydrochloric acid-based decalcification for more than half of the specimens. When both EDTA and hydrochloric acid decalcification were present, hydrochloric acid decalcification was prioritized.
Results
In our hospital, 74 thyroid carcinoma cases were tested using the Oncomine Dx Target Test between July 2022 and October 2023. This excludes one case in which the test was canceled owing to a low tumor cell count and prior hydrochloric acid decalcification. The histological types are as follows: PTC in 66 cases, follicular thyroid carcinoma (FTC) in three cases, poorly differentiated thyroid carcinoma (PDTC) in four cases, and medullary thyroid carcinoma (MTC) in one case. No anaplastic thyroid carcinomas were present. Genetic analysis revealed that PTC primarily exhibited the BRAF V600E mutation (47 out of 66 PTC cases, 71.2%), whereas FTC exclusively showed RAS mutations (three out of three FTC cases, 100%). The RET fusion gene was detected in eight cases (8/74, 10.8%), whereas the NTRK3 fusion gene was detected in one case (1/74, 1.4%). No other fusion genes, including ALK, ROS1, and PPARG, were detected. Detailed data are summarized in Supporting Information 1. Among the nine cases exhibiting the fusion genes, the median patient age was 53 years, and the male-to-female ratio was 2:7. None of the nine patients in this study had a history of radiation exposure. For the response to RAI therapy, six cases exhibited a “structural incomplete response,” two cases exhibited an “indeterminate response,” and one case did not receive RAI therapy. In the cases with the fusion genes, primary tumors were confirmed in only seven cases (1, 2, 4, 6, 7, 8, and 9) in our hospital. Moreover, in two cases (3 and 5), we could not obtain the primary tumor because they involved surgeries performed at external hospitals. Most of the patients were diagnosed with PTC. Only one patient (case 9) exhibited lymph node metastases characteristics of a PDTC. All of the obtained cases, except for PDTC in case 9, had PTC nuclei. In addition, detailed examination revealed “BRAF-like” atypia in cases 2–4, 6, 8, and 9, and “RAS-like” atypia in cases 1, 5, and 7 (Fig. 1b–c). Note that case 9 was assessed only on the primary tumor, as the lymph node metastases had progressed to PDTC. The mitoses of the primary tumors were all < 1 per 10 high-power fields. Lymphatic invasion was observed in two cases (cases 1 and 4; 28.6%, 2/7), whereas vascular invasion was observed in all cases. Squamous solid nests were confirmed in three cases (cases 1, 2, and 4; 42.9%, 3/7). Immunohistochemical examination revealed a median Ki-67 labeling index of 1.3% for primary tumors. All cases were negative for BRAF V600E, both in immunoreactivity (Fig. 2c) and mutations. Immunoreactivity of Pan-TRK was negative in case 7 (Fig. 2d), which had the ETV6::NTRK3 fusion gene. These clinicopathological data are summarized in Table 1. Pathologically, in primary tumors, the median percentage of papillary structures was 50%, and follicular and STI structures were observed (Fig. 2a, b) while lymph node metastases exhibited a more pronounced papillary structure. The prevalence of STI structures in the lymph node groups was low. Moreover, dysmorphic clear cells, identified by highly compressed nuclei and pale-to-clear cytoplasm, were observed to varying degrees in all cases except case 4 (Fig. 1a, b). The median percentage of fibrosis in the primary tumors was 40%. In the lymph node groups, the median percentages were 20% in the N1a group and less than 10% in the N1b group. A decalcification procedure was necessary in the majority case of primary tumors but it was not needed for the N1b lymph node except for one case (Fig. 3a–d and Table 2). Furthermore, in our study, while none of the nine cases completely matched the essential criteria for DSVPTC [9], several distinct characteristics were observed. These included a predominantly young and female patient population and significant occurrence of RAI resistance. Additionally, features such as intraglandular dissemination, lymphatic invasion, squamous solid nests, and/or chronic thyroiditis were confirmed in some cases. Varying degrees of fibrosis and patterns of follicular or STI structures were also observed across many cases. These data are summarized in Supporting Information 2.
Discussion
Recently, the importance of molecular-targeted drugs in the treatment of thyroid carcinoma has been increasingly recognized [3, 4, 14,15,16]. Although the significance of BRAF inhibitors is well established, the role of targeted therapies for the fusion genes (such as RET, NTRK, ALK fusion genes) is also important [17, 18]. Notably, BRAF mutations are mutually exclusive with these fusion genes [19, 20]. Therefore, the efficient detection of these fusion genes is important for the selection of appropriate molecular-targeted therapies. Of course, recent advancements in preoperative molecular testing for genes have significantly aided early thyroid carcinoma diagnosis [1, 3, 15, 16]. However, limitations such as sampling variability and the heterogeneous nature of cancer can affect the comprehensiveness of these tests [21, 22]. The cost of testing is also an issue [21, 23, 24]. Considering economic and insurance constraints, it is important to establish a process that can detect cases with these fusion genes from routine diagnostic work. Our study, which analyzed surgical specimens, complements this approach by providing a more comprehensive molecular and histological assessment.
In thyroid carcinoma, the frequency of RET fusion genes ranges from approximately 6 to 10% [25,26,27,28], which aligns with our results. Similarly, the frequency of NTRK fusion genes ranges from 2 to 7% [26, 29,30,31,32]. However, the frequency of NTRK fusion genes in our study was lower. This discrepancy could be attributed to several factors. First, in our analysis, we used the Oncomine Dx Target Test, approved in Japan only for advanced or recurrent cases. Second, our study had a comparatively small sample size. Final, the detection of the NTRK fusion gene using the Oncomine Dx Target Test could be limited owing to difficulties in covering relevant intron regions, in which the NTRK fusion breakpoints commonly occur [33]. The frequency of ALK fusion genes in thyroid carcinoma ranges from approximately 1 to 4% [34,35,36], with a slightly higher frequency of 6% in pediatric PTC cases [37]. However, in our study, we did not detect any ALK fusion genes, which may have the same issues as those found with NTRK fusion genes. Moreover, our patient cohort included advanced cases, most of which were RAI therapy-resistant. This might introduce a selection bias. In addition, among the 66 PTC cases (10/66, 15.2%), ten exhibited no identifiable genetic alterations. A recent report indicates that the categorization of such PTC cases with no initial driver event identification as “dark matter” PTCs might be premature [9]. The absence of detectable genetic alterations in these cases may be because of limitations of the testing methods and may require a more comprehensive diagnostic approach, if necessary.
In our histological analysis, we observed the presence of non-papillary (follicular and/or STI) structures, compressed nuclei, and cells with clear to pale cytoplasm (reminiscent of dysmorphic clear cells), along with notable fibrosis and calcification. These features were prevalent in several cases, suggesting distinct histological patterns. Given that BRAF V600E mutations in papillary thyroid carcinomas are associated with distinct morphological features, including a well-developed papillary architecture [38], it can be hypothesized that non-papillary structures may be more pronounced in thyroid carcinomas with RET and/or NTRK3 fusion genes. In addition, case 7, the sole case with a detected NTRK3 fusion gene, exhibited “RAS-like” atypia. Each case with a RET fusion gene presented distinct morphologic features, with some cases showing “BRAF-like” atypia (cases 2–4, 6, 8, and 9) and others exhibiting “RAS-like” atypia (cases 1 and 5). This variability in cases with RET fusion genes and “RAS-like” atypia in cases with NTRK fusion genes is consistent with that in a previous report [9] and underscores the morphological distinctions associated with these specific genetic changes. In addition, dysmorphic clear cells were observed in both decalcified primary tumors and non-decalcified lymph node metastases, indicating morphological consistency between the different specimen preparations. Despite the small number of cases, the overall morphology of the cases with the RET fusion gene and the NTRK3 fusion gene was similar. This finding is consistent with that of a previous report on sarcoma cases with these fusion genes [39]. In this study, all cases with detected fusion genes exhibited negative immunoreactivity for BRAF V600E. These findings suggested a high probability of the presence of the RET or NTRK fusion genes in cases with various structural patterns, dysmorphic clear cells, and background fibrosis and/or calcification. However, as confirmed in case 4, the absence of these morphological characteristics does not indicate the absence of these fusion genes, emphasizing the limitations of morphological assessment alone. Nevertheless, the negative immunoreactivity for BRAF V600E in all cases indicates that the combination of morphological analysis with immunohistochemistry may improve the prediction for thyroid carcinoma harboring the RET and/or NTRK fusion genes. It should be noted, however, that Pan-TRK immunohistochemistry may not always yield positive results in cases with the ETV6::NTRK3 fusion gene, as previously reported [9].
Meanwhile, our cases exhibited some similarities to those of DSVPTC. These included a relatively young patient population and the occurrence of RAI resistance. Intraglandular dissemination, lymphatic invasion, squamous solid nests, and/or chronic thyroiditis were noted in some cases. Additionally, varying degrees of fibrosis and patterns of follicular or STI architecture were observed across many cases. However, it is important to recognize that in Japan, the Oncomine Dx Target Test is used primarily in advanced or recurrent cases. This specific limitation for the use of the test may explain the lack of definite DSVPTC in our series. Despite this, the clinicopathological similarities we observed suggest a potential association between thyroid carcinomas with detected fusion genes and DSVPTC. Furthermore, some reports have suggested that thyroid carcinomas with the RET and/or NTRK fusion genes tend to be aggressive [28, 29, 40, 41]; our findings indicate a more complex scenario. Although all our cases showed low mitotic activity and a low Ki-67 labeling index, distant metastases were observed in cases 1–8, and a PDTC component was present in case 9. This implies that the level of aggressiveness was not fully captured by these markers.
We would like to shed some light on the challenges and considerations in decalcification processes, particularly in thyroid carcinoma harboring fusion genes and varying degrees of calcification. In our hospital, the choice between EDTA-based and hydrochloric acid-based decalcification depended on the degree of calcification. EDTA-based decalcification is preferred to preserve nucleic acid quality [42, 43], which is important for detecting fusion genes. However, in cases of more severe calcification, which prevents sectioning for pathological diagnosis, hydrochloric acid-based decalcification is required despite the risk of affecting nucleic acid quality [42, 43]. In this study, significant calcification was observed in many primary tumors that required hydrochloric acid-based decalcification. In contrast, calcification in the lymph node metastases, particularly in the N1b group, tended to be mild. These findings suggest that lymph node metastases, particularly those in the N1b group, may be more suitable for genetic analysis of thyroid carcinoma cases. The reason for the mild calcification in the lymph node metastases is unclear. In our study, younger patients, such as those in cases 1 and 2, exhibited mild calcification of the primary tumor. This finding implies that mild calcification in lymph node metastases may reflect their recent occurrence compared to primary tumors. As these metastatic cells are derived from a late-stage primary tumor, their stay in the lymph nodes is relatively short, which may result in mild calcification. However, as lymph nodes are located in adipose tissues and are covered by a capsule [44], it may be necessary to remove the surrounding adipose tissue and make special incisions to obtain the specimen to ensure proper formalin fixation for genetic analysis.
In conclusion, our study has identified unique pathological characteristics associated with the RET and NTRK3 fusion genes in thyroid carcinoma cases, such as non-papillary structures, compressed nuclei, dysmorphic clear cells, calcification, and similarities with DSVPTC. These characteristics could serve as indicators for considering fusion gene testing. Additionally, our analysis of the varying degrees of calcification between primary tumors and lymph node metastases, particularly in the N1b group, underscores the importance of precise sample processing for efficient genetic analysis. Put together, these insights contribute to a more targeted approach in the molecular diagnosis and treatment of thyroid carcinomas (details in Supporting Information 3).
Limitations
This study has several limitations. This study involved a limited number of cases and subjective pathology analysis. As the Oncomine Dx Target Test is approved only for advanced or recurrent thyroid carcinoma cases in Japan, there may have been bias in the analyzed cases. Moreover, decisions regarding the selection of decalcification procedures (EDTA- or hydrochloric acid-based) depended on the judgment of the clinical laboratory technicians.
Data availability
The datasets used and/or analyzed during this study are available from the corresponding author upon reasonable request.
Code availability
Not applicable.
References
Haroon Al Rasheed MR, Xu B (2019) Molecular alterations in thyroid carcinoma Surg Pathol Clin 12:921–930. https://doi.org/10.1016/j.path.2019.08.002
Lee YA, Lee H, Im SW, Song YS, Oh DY, Kang HJ, Won JK, Jung KC, Kwon D, Chung EJ, Hah JH, Paeng JC, Kim JH, Choi J, Kim OH, Oh JM, Ahn BC, Wirth LJ, Shin CH, Kim JI, Park YJ (2021) NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake J Clin Invest 131. https://doi.org/10.1172/JCI144847
Capdevila J, Awada A, Fuhrer-Sakel D, Leboulleux S, Pauwels P (2022) Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 106:102380. https://doi.org/10.1016/j.ctrv.2022.102380
Cabanillas ME, Ryder M, Jimenez C (2019) Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev 40:1573–1604. https://doi.org/10.1210/er.2019-00007
Christofyllakis K, Bittenbring JT, Thurner L, Ahlgrimm M, Stilgenbauer S, Bewarder M, Kaddu-Mulindwa D (2022) Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review). Mol Clin Oncol 16:21. https://doi.org/10.3892/mco.2021.2453
Gavan SP, Thompson AJ, Payne K (2018) The economic case for precision medicine Expert Rev Precis Med Drug Dev 3:1–9. https://doi.org/10.1080/23808993.2018.1421858
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM (2015) Wartofsky L (2016). American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer Thyroid 26:1–133. https://doi.org/10.1089/thy.2015.0020
Thompson LDR, Poller DN, Kakudo K, Burchette R, Nikiforov YE, Seethala RR (2018) An international interobserver variability reporting of the nuclear scoring criteria to diagnose noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a validation study. Endocr Pathol 29:242–249. https://doi.org/10.1007/s12022-018-9520-0
Chou A, Qiu MR, Crayton H, Wang B, Ahadi MS, Turchini J, Clarkson A, Sioson L, Sheen A, Singh N, Clifton-Bligh RJ, Robinson BG, Gild ML, Tsang V, Leong D, Sidhu SB, Sywak M, Delbridge L, Aniss A, Wright D, Graf N, Kumar A, Rathi V, Benitez-Aguirre P, Glover AR, Gill AJ (2023) A detailed histologic and molecular assessment of the diffuse sclerosing variant of papillary thyroid carcinoma. Mod Pathol 36:100329. https://doi.org/10.1016/j.modpat.2023.100329
Thompson LD, Wieneke JA, Heffess CS (2005) Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases. Endocr Pathol 16:331–348. https://doi.org/10.1385/ep:16:4:331
Carcangiu ML, Bianchi S (1989) Diffuse sclerosing variant of papillary thyroid carcinoma Clinicopathologic study of 15 cases. Am J Surg Pathol 13:1041–1049. https://doi.org/10.1097/00000478-198912000-00006
Chan JK, Tsui MS, Tse CH (1987) Diffuse sclerosing variant of papillary carcinoma of the thyroid: a histological and immunohistochemical study of three cases. Histopathology 11:191–201. https://doi.org/10.1111/j.1365-2559.1987.tb02622.x
Das DK (2009) Psammoma body: a product of dystrophic calcification or of a biologically active process that aims at limiting the growth and spread of tumor? Diagn Cytopathol 37:534–541. https://doi.org/10.1002/dc.21081
Okubo Y, Toda S, Sato S, Yoshioka E, Ono K, Hasegawa C, Washimi K, Yokose T, Miyagi Y, Iwasaki H, Hayashi H (2023) Histological findings of thyroid cancer after lenvatinib therapy. Histopathology 83:657–663. https://doi.org/10.1111/his.15013
Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M (2023) Molecular basis and targeted therapy in thyroid cancer: progress and opportunities Biochim Biophys Acta Rev. Cancer 1878:188928. https://doi.org/10.1016/j.bbcan.2023.188928
Miller KC, Chintakuntlawar AV (2021) Molecular-driven therapy in advanced thyroid cancer. Curr Treat Options Oncol 22:24. https://doi.org/10.1007/s11864-021-00822-7
Hamidi S, Hofmann MC, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R (2023) Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance Front Endocrinol (Lausanne) 14:1176731. https://doi.org/10.3389/fendo.2023.1176731
Toda S, Iwasaki H, Okubo Y, Hayashi H, Kadoya M, Takahashi H, Yokose T, Hiroshima Y, Masudo K (2023). The frequency of mutations in advanced thyroid cancer in Japan: a single-center study Endocr J. https://doi.org/10.1507/endocrj.EJ23-0342
Marchetti A, Ferro B, Pasciuto MP, Zampacorta C, Buttitta F, D'Angelo E (2022) NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies Pathologica 114:199–216. https://doi.org/10.32074/1591-951X-787
Chu YH, Sadow PM (2021) Kinase fusion-related thyroid carcinomas: distinct pathologic entities with evolving diagnostic implications Diagn Histopathol (Oxf) 27:252–262. https://doi.org/10.1016/j.mpdhp.2021.03.003
Khan TM, Zeiger MA (2020) Thyroid nodule molecular testing: is it ready for prime time? Front Endocrinol (Lausanne) 11:590128. https://doi.org/10.3389/fendo.2020.590128
Roth MY, Witt RL, Steward DL (2018) Molecular testing for thyroid nodules: review and current state. Cancer 124:888–898. https://doi.org/10.1002/cncr.30708
McMurtry V, Canberk S, Deftereos G (2023) Molecular testing in fine-needle aspiration of thyroid nodules. Diagn Cytopathol 51:36–50. https://doi.org/10.1002/dc.25035
Ontario H (2022) Molecular testing for thyroid nodules of indeterminate cytology: a health technology assessment Ont Health Technol Assess Ser 22:1–111
Shi M, Wang W, Zhang J, Li B, Lv D, Wang D, Wang S, Cheng D, Ma T (2022) Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing. Cancer Sci 113:308–318. https://doi.org/10.1111/cas.15181
Hescheler DA, Riemann B, Hartmann MJM, Michel M, Faust M, Bruns CJ, Alakus H, Chiapponi C (2021) Targeted therapy of papillary thyroid cancer: a comprehensive genomic analysis Front Endocrinol (Lausanne) 12:748941. https://doi.org/10.3389/fendo.2021.748941
Parimi V, Tolba K, Danziger N, Kuang Z, Sun D, Lin DI, Hiemenz MC, Schrock AB, Ross JS, Oxnard GR, Huang RSP (2023) Genomic landscape of 891 RET fusions detected across diverse solid tumor types NPJ Precis Oncol 7:10. https://doi.org/10.1038/s41698-023-00347-2
Bulanova Pekova B, Sykorova V, Mastnikova K, Vaclavikova E, Moravcova J, Vlcek P, Lancova L, Lastuvka P, Katra R, Bavor P, Kodetova D, Chovanec M, Drozenova J, Matej R, Astl J, Hlozek J, Hrabal P, Vcelak J, Bendlova B (2023) RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis Endocr Relat Cancer 30. https://doi.org/10.1530/ERC-23-0117
Pekova B, Sykorova V, Mastnikova K, Vaclavikova E, Moravcova J, Vlcek P, Lastuvka P, Taudy M, Katra R, Bavor P, Kodetova D, Chovanec M, Drozenova J, Astl J, Hrabal P, Vcelak J, Bendlova B (2021) NTRK fusion genes in thyroid carcinomas: clinicopathological characteristics and their impacts on prognosis Cancers (Basel) 13. https://doi.org/10.3390/cancers13081932
Koehler VF, Achterfeld J, Sandner N, Koch C, Wiegmann JP, Ivanyi P, Kasmann L, Pusch R, Wolf D, Chirica M, Knosel T, Demes MC, Kumbrink J, Vogl TJ, Meyer G, Spitzweg C, Bojunga J, Kroiss M (2023) NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer. J Cancer Res Clin Oncol 149:14035–14043. https://doi.org/10.1007/s00432-023-05134-x
Rosen EY, Goldman DA, Hechtman JF, Benayed R, Schram AM, Cocco E, Shifman S, Gong Y, Kundra R, Solomon JP, Bardelli A, Scaltriti M, Drilon A, Iasonos A, Taylor BS, Hyman DM (2020) TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations. Clin Cancer Res 26:1624–1632. https://doi.org/10.1158/1078-0432.CCR-19-3165
Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, Hyman DM, Ladanyi M, Sireci AN, Hechtman JF (2020) NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls Mod Pathol 33:38–46. https://doi.org/10.1038/s41379-019-0324-7
Solomon JP, Hechtman JF (2019) Detection of NTRK fusions: merits and limitations of current diagnostic platforms. Cancer Res 79:3163–3168. https://doi.org/10.1158/0008-5472.CAN-19-0372
Chou A, Fraser S, Toon CW, Clarkson A, Sioson L, Farzin M, Cussigh C, Aniss A, O’Neill C, Watson N, Clifton-Bligh RJ, Learoyd DL, Robinson BG, Selinger CI, Delbridge LW, Sidhu SB, O’Toole SA, Sywak M, Gill AJ (2015) A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol 39:652–659. https://doi.org/10.1097/PAS.0000000000000368
Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052–1066. https://doi.org/10.1172/JCI85271
Cancer Genome Atlas Research N (2014) Integrated genomic characterization of papillary thyroid carcinoma Cell 159:676–690. https://doi.org/10.1016/j.cell.2014.09.050
Pekova B, Sykorova V, Dvorakova S, Vaclavikova E, Moravcova J, Katra R, Astl J, Vlcek P, Kodetova D, Vcelak J, Bendlova B (2020) RET, NTRK, ALK, BRAF, and MET Fusions in a large cohort of pediatric papillary thyroid carcinomas Thyroid 30:1771–1780. https://doi.org/10.1089/thy.2019.0802
Turchini J, Sioson L, Clarkson A, Sheen A, Delbridge L, Glover A, Sywak M, Sidhu S, Gill AJ (2023) The presence of typical “BRAFV600E-Like” atypia in papillary thyroid carcinoma is highly specific for the presence of the BRAFV600E mutation Endocr Pathol 34:112–118. https://doi.org/10.1007/s12022-022-09747-9
Antonescu CR, Dickson BC, Swanson D, Zhang L, Sung YS, Kao YC, Chang WC, Ran L, Pappo A, Bahrami A, Chi P, Fletcher CD (2019) Spindle cell tumors with RET gene fusions exhibit a morphologic spectrum akin to tumors with NTRK gene fusions. Am J Surg Pathol 43:1384–1391. https://doi.org/10.1097/PAS.0000000000001297
Ullmann TM, Thiesmeyer JW, Lee YJ, Beg S, Mosquera JM, Elemento O, Fahey TJ 3rd, Scognamiglio T, Houvras Y (2022). RET fusion-positive papillary thyroid cancers are associated with a more aggressive phenotype Ann Surg Oncol. https://doi.org/10.1245/s10434-022-11418-2
Ma Y, Zhang Q, Zhang K, Liang Y, Ren F, Zhang J, Kan C, Han F, Sun X (2023) NTRK fusions in thyroid cancer: pathology and clinical aspects. Crit Rev Oncol Hematol 184:103957. https://doi.org/10.1016/j.critrevonc.2023.103957
Miquelestorena-Standley E, Jourdan ML, Collin C, Bouvier C, Larousserie F, Aubert S, Gomez-Brouchet A, Guinebretiere JM, Tallegas M, Brulin B, Le Nail LR, Tallet A, Le Loarer F, Massiere J, Galant C, de Pinieux G (2020) Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samples. Mod Pathol 33:1505–1517. https://doi.org/10.1038/s41379-020-0503-6
Singh VM, Salunga RC, Huang VJ, Tran Y, Erlander M, Plumlee P, Peterson MR (2013) Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies Ann Diagn Pathol 17:322–326. https://doi.org/10.1016/j.anndiagpath.2013.02.001
Priya NS (2023) Lymph nodes in health and disease—a pathologist’s perspective J Oral Maxillofac Pathol 27:6–11. https://doi.org/10.4103/jomfp.jomfp_40_23
Acknowledgements
We thank Editage (www.editage.jp) for their assistance with English language editing.
Funding
This work was supported by the JSPS KAKENHI grant (grant number 17K08713; granted to Yoichiro Okubo) from the Ministry of Education, Culture, Sports, Science, and the Technology of Japan and Kanagawa Cancer Center and Research Institute/Kanagawa Prefectural Hospital Organization (grant numbers 2023–1 and 2023-Gankikin; granted to Yoichiro Okubo).
Author information
Authors and Affiliations
Contributions
YO reviewed the specimens, collected and integrated the clinicopathological data, and wrote the manuscript. ST and MK provided clinical information from an endocrine surgery perspective and answered questions from YO. SS was primarily responsible for immunohistochemical and genetic analysis. EY, CH, KO, and KW reviewed the specimens from a pathological perspective, discussed the manuscript draft with YO, and suggested revisions. TY and YM revised the parts of the manuscript regarding pathological diagnoses. KM and HI provided clinical information and revised parts of the manuscript with YO. HH reviewed thyroid specimens, systematically evaluated histological changes, and revised the manuscript. All authors read and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Ethical approval
Written informed consent was obtained from all patients for participation and publication of the study data. This study was performed in accordance with the tenets of the Declaration of Helsinki and was approved by the Ethics Review Committee of Kanagawa Cancer Center (approval number: 2021–88; October 11, 2021).
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Okubo, Y., Toda, S., Kadoya, M. et al. Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis. Virchows Arch 485, 509–518 (2024). https://doi.org/10.1007/s00428-024-03777-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-024-03777-w